Antimicrobial Susceptibility Testing Market by Product (Manual, Automated Susceptibility Testing System), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion), End-User - Global Forecasts to 2025
[220 Pages Report] The antimicrobial susceptibility testing market is projected to reach USD 4.2 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 5.5% during the forecast period. The increasing prevalence of infections due to bacterial pathogens and overuse of antibiotics─ which leads to antibiotic resistance in bacterial organisms; development of better standards for fungal susceptibility, and the increasing use of rapid commercial AST systems for fungal testing are the key factors supporting the growth of the market.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on the global AST market
As a result of the pandemic, during March 2020 and throughout the second quarter of 2020, access to customers to sell and implement the automated AST systems (such as Accelerate Pheno system, MicroScan WalkAway, and Sensitire ARIS system) diminished as hospitals became primarily focused on the COVID-19 pandemic. The limited access to current and potential customers has significantly reduced market players’ ability to complete sales of new AST systems and to implement previously sold systems, thereby reducing the growth of consumable test kits. Furthermore, the market is expecting to recover the losses by the fourth quarter of 2020.
AST Market Dynamics
Driver: Rising incidence of infectious diseases coupled with epidemic & pandemic events
The growing number of epidemic outbreaks caused by infectious pathogens such as Haemophilus influenzae, Neisseria meningitides, Streptococcus pneumoniae, Shigella, Vibrio cholera, Neisseria gonorrhoeae, and Salmonella serotype Typhi is also propelling the demand for antimicrobial susceptibility testing products. Listed below are statistics regarding the increased incidence of several major infectious diseases in recent years:
- According to the WHO, TB is one of the top 10 causes of death and the leading cause of a single infectious agent. In 2018, 10 million people across the globe were estimated to be suffering from tuberculosis, of which 1.5 million people died due to the disease.
- According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), globally, 1.7 million people were newly infected with HIV in 2019, 38 million people are living with HIV, and 690 thousand people died of AIDS-related illnesses.
- According to the World Malaria Report 2019, an estimated 228 million cases of malaria were diagnosed worldwide. The report further stated that the nineteen countries in sub-Saharan Africa and India carried almost 85% of the global malaria burden.
Restraint: High cost of automated ID/AST systems
Automated antimicrobial susceptibility testing instruments are equipped with highly advanced features and functionalities and are priced at premium rates. The use of automated AST systems reduces the incubation and detection time. However, the high cost of these systems is a major restraining factor for their widespread adoption by end-users, especially for small-budget institutions.
Opportunity: Awareness initiatives for antimicrobial resistance and its control
Antimicrobial susceptibility tests play a significant role in detecting the resistance of bacteria to antibiotics. Healthcare authorities are increasingly becoming aware of the significance of antimicrobial susceptibility to ensure the efficacy and safety of AST methods. Various initiatives—for instance, the Global Sepsis Alliance (GSA), a non-profit organization located in the US, works to support over one million caregivers in more than 70 countries and increase awareness about sepsis and its management. Likewise, in the US, the CDC launched a new website, Antibiotic / Antimicrobial Resistance (AR / AMR), to increase AMR awareness and support the early recognition, diagnosis, and treatment of antibiotic resistance. Along with this, various local government and intergovernmental organizations such as the WHO, EU, Transatlantic Task Force on Antimicrobial Resistance (TATFAR), and Global Health Security Agenda (GHSA) are developing and implementing plans and efforts to tackle antimicrobial resistance.
Challenge: Complex regulatory frameworks that delay antimicrobial testing approvals
Among the major challenges faced by the AST market is the time lapse between establishing clinical breakpoints, approval of new antimicrobial agents, and the inclusion of these agents in antimicrobial susceptibility testing. The FDA establishes these breakpoints when drug manufacturers submit individual new drug applications or when device manufacturers submit requests to revise the breakpoints. Furthermore, the unavailability of clinical breakpoints for certain drugs is also limiting the adoption of AST products.
To know about the assumptions considered for the study, download the pdf brochure
By product, the manual antimicrobial susceptibility testing products segment dominated the global antimicrobial susceptibility testing market
Based on the product, the antimicrobial susceptibility testing market is segmented into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. Manual antimicrobial susceptibility testing products include susceptibility testing disks, MIC strips, and susceptibility testing plates. The manual susceptibility testing products segment dominated the AST market in 2019. Rising incidences of antibacterial resistance, new product launches, coupled with the rising adoption of susceptibility testing disks in emerging countries, is expected to drive the segment growth.
Antibacterial susceptibility testing segment to account for the largest share of the AST market, by type, in 2025
Based on type, the antimicrobial susceptibility testing market has been segmented into the antibacterial, antifungal, antiparasitic, and other susceptibility testing types. Among these, the antibacterial susceptibility testing segment accounted for the largest share of the market in 2019. The major share of this segment can be attributed to the overuse of a broad-spectrum of antibiotics, the emergence of multidrug-resistance. The overuse of broad-spectrum antibiotics results in the development of drug resistance in pathogens, thereby increasing the need for better screening of drugs. Early availability of information on bacterial pathogens and their antimicrobial susceptibility help in the timely adoption of the appropriate treatment therapy, playing an important role in disease management.
By application, the clinical diagnostics segment accounted for the largest share of the AST market in 2019
Based on application, the antimicrobial susceptibility testing market has been segmented into the market is segmented into clinical diagnostics, drug discovery and development, epidemiology, and other applications. Among these, the clinical diagnostics segment accounted for the largest share of the market in 2019. The large share of this segment is attributed to the rising prevalence of infectious diseases, increasing incidence of HAIs, large target patient population base (especially in emerging countries), the growing procedural volume of clinical diagnostic tests, rising emphasis on effective and early disease diagnosis across major markets, and the introduction of various technologically advanced susceptibility testing products.
Automated antimicrobial susceptibility testing instruments dominated the AST market, by method, in 2019; this trend to continue during the forecast period
Based on the method, the antimicrobial susceptibility testing market has been segmented into disk diffusion, agar dilution, ETEST, automated antimicrobial susceptibility testing instruments, and genotypic methods. Among these methods, the automated antimicrobial susceptibility testing instruments segment accounted for the largest share of the market in 2019. The major share of the segment is predominantly driven by its speed, accuracy, and ability to give qualitative and quantitative susceptibility results. Moreover, technological advancements and rising R&D investments by key players to deliver novel technologies in the market are factors driving the growth of the segment.
North America is expected to command the largest share of the AST market in 2019
The report covers the AST market across five major geographies, namely, Europe, North America, Asia Pacific, Latin America, and MEA. North America commanded the largest share of the AST market in 2019. The increasing R&D to develop novel automated AST systems, rising prevalence of infectious diseases, safety concerns, and technological advancements in antimicrobial susceptibility products are the key factors supporting market growth in North America. Moreover, most of the prominent companies in the global market are headquartered in the region or have a strong presence in this market, such as Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Bruker Corporation. Others have focused on expansion to increase their reach and capabilities. This is another key factor attributed to the prominent growth of the market.
Key Market Players
The major players in the AST market are bioMérieux SA (France), Becton, Dickinson, and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), and Bio-Rad Laboratories, Inc. (US). The other prominent players operating in this market include Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), Hi-Media Laboratories (India), Liofilchem S.r.l. (Italy), Alifax S.r.l. (Italy), Creative Diagnostics (US), Synbiosis (UK), Bioanalyse (Turkey), ZHUHAI DL BIOTECH Co., Ltd. (China), ELITechGroup (France), Mast Group Ltd. (UK), CONDALAB (Spain), Genefluidics, Inc. (US), Biotron Ltd (Australia), InvivoGen (US), MP Biomedicals (US), QuantaMatrix Inc. (South Korea), and PML Microbiologicals Inc. (US), among others.
bioMérieux SA is a leader in the global AST market. bioMérieux is a developer of innovative solutions for clinical diagnostics and industrial microbiological control in fields such as the agri-food sector, environmental monitoring, and veterinary diagnostics. The comprehensive range of products, high focus on R&D (to deliver novel products in the market), and strong geographical presence are the key factors contributing to the major market share of the company in the AST market. The company has focused extensively on R&D efforts in the field of antimicrobial resistance, with around 75% of the company’s R&D budget dedicated to antimicrobial resistance. This heavy investment in R&D is driving the company’s launch of new and technologically improved products.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2018–2025 |
|
Base year considered |
2019 |
|
Forecast period |
2020–2025 |
|
Forecast units |
Value (USD Billion) |
|
Segments covered |
Technology, Device Display, System Portability, Application, End User, and Region |
|
Geographies covered |
Europe, North America, the Asia Pacific, Latin America, and Middle East and Africa |
|
Companies covered |
bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), Hi-Media Laboratories (India), Liofilchem S.r.l. (Italy), Alifax S.r.l. (Italy), Creative Diagnostics (US), Synbiosis (UK), Bioanalyse (Turkey), ZHUHAI DL BIOTECH Co., Ltd. (China), ELITechGroup (France), Mast Group Ltd. (UK), CONDALAB (Spain), Genefluidics, Inc. (US), Biotron Ltd (Australia), InvivoGen (US), MP Biomedicals (US), QuantaMatrix Inc. (South Korea), and PML Microbiologicals Inc. (US), among others |
This report has segmented the global AST market based on product, type, method, application, end user, and region.
Global Antimicrobial Susceptibility Testing Market, by Product
- Manual Antimicrobial Susceptibility Testing Products
- Susceptibility Testing Disks
- MIC Strips
- Susceptibility Testing Plates
- Automated Laboratory Instruments
- Culture and Growth Media
- Consumables
Global Antimicrobial Susceptibility Testing Market, by Type
- Antibacterial Susceptibility Testing
- Antifungal Susceptibility Testing
- Antiparasitic Susceptibility Testing
- Other Susceptibility Testing Types (slow-growing pathogens)
Global Antimicrobial Susceptibility Testing Market, by Method
- Etest Method
- Disk Diffusion
- Automated Susceptibility Testing Instruments
- Agar Dilution
- Genotyping Methods
Global Antimicrobial Susceptibility Testing Market, by Application
- Clinical Diagnostics
- Drug Discovery and Development
- Epidemiology
- Other Applications (Research and academic applications, bioterrorism surveillance, and environmental monitoring)
Global Antimicrobial Susceptibility Testing Market, by End User
- Hospitals and Diagnostic Centers
- Pharmaceutical and Biotechnology Companies
- Research &Academic Institutes
- Clinical Research Organizations (CROs)
Global Antimicrobial Susceptibility Testing Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Middle East & Africa
Recent Developments
- In 2020, Liofilchem received the US FDA approval for its Lefamulin 0.016-256 μg/mL MTS (MIC Test Strip). It is a quantitative assay for determining the Minimum Inhibitory Concentration (MIC) of lefamulin.
- In 2019, Alifax introduced an innovative diagnostic instrumentation portfolio at the MEDICA trade fair held in Germany. The company’s diagnostic instrumentation portfolio includes Test1 and Roller 20 for the analysis of ESR; Alfred AST sepsis analyzer for RAPID Bacterial Culture; antimicrobial susceptibility testing and MDRO screening, and ALIBOX systems.
- In 2019, The company launched the Sensititre ARIS HiQ AST System, an automated reading and incubation system for antimicrobial susceptibility testing (AST) in Europe. The company also introduced this system at the 71st American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition held in the US.
Frequently Asked Questions (FAQ):
How big is the Antimicrobial Susceptibility Testing Market?
Antimicrobial Susceptibility Testing Market worth $4.2 billion by 2025.
What is the growth rate of Antimicrobial Susceptibility Testing Market?
Antimicrobial Susceptibility Testing Market grows at a CAGR of 5.5% during the forecast period.
What is the expected addressable market value of major AST products over a 5-year period?
The antimicrobial susceptibility testing market is projected to reach USD 4.20 billion by 2025 from USD 3.22 billion in 2020, at a CAGR of 5.5% during the forecast period.
Which product segment is expected to garner highest traction within the AST market?
Based on product, the antimicrobial susceptibility testing market is segmented into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. The manual susceptibility testing products segment dominated the AST market in 2019. Rising incidences of antibacterial resistance and new product launches expected to drive the segment growth.
What are the strategies adopted by the top market players to penetrate across emerging regions?
The key growth strategies adopted by the top players in this market include product launches and approvals; agreements and partnerships; expansions; and acquisitions.
What are the major factors expected to limit the growth of the AST market?
The high cost of automated antimicrobial susceptibility testing systems is expected to limit market growth in the coming years. Moreover, complex regulatory frameworks that delay the approval of new microbial susceptibility tests are also expected to challenge market growth to a certain extent.
What is the adoption pattern for novel AST products across major healthcare markets?
In North America, conventional methods (phenotypic methods) for susceptibility testing are witnessing stagnant growth. However, the introduction of new proteomic identification methods is expected to drive market growth in the region.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH DATA
FIGURE 1 GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: RESEARCH METHODOLOGY STEPS
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.2 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 VENDOR REVENUE-BASED MARKET ESTIMATION
FIGURE 5 VENDOR REVENUE-BASED MARKET ESTIMATION
2.2.2 END USER-BASED MARKET SIZE ESTIMATION
FIGURE 6 ANTIMICROBIAL SUSCEPTIBILITY TEST MARKET: END USER-BASED ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 44)
FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TEST MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 9 ANTIMICROBIAL SUSCEPTIBILITY TEST MARKET SHARE, BY TYPE, 2020 VS. 2025
FIGURE 10 ANTIMICROBIAL SUSCEPTIBILITY TEST MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 11 ANTIMICROBIAL SUSCEPTIBILITY MARKET SHARE, BY METHOD, 2020 VS. 2025 (USD MILLION)
FIGURE 12 ANTIMICROBIAL SUSCEPTIBILITY MARKET SHARE, BY END USER, 2020 VS. 2025
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ANTIMICROBIAL SUSCEPTIBILITY MARKET
4 PREMIUM INSIGHTS (Page No. - 49)
4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING: MARKET OVERVIEW
FIGURE 14 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE ARE THE MAJOR FACTORS DRIVING THE GROWTH OF THE ANTIMICROBIAL SUSCEPTIBILITY MARKET ACROSS THE GLOBE
4.2 GEOGRAPHIC ANALYSIS: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2020 VS 2025, (USD MILLION)
FIGURE 15 THE AUTOMATED LABORATORY INSTRUMENTS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2025
4.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020 VS 2025, (USD MILLION)
FIGURE 16 THE SUSCEPTIBILITY TESTING DISKS SUBSEGMENT IS EXPECTED TO DOMINATE THE MARKET, BY TYPE, DURING THE FORECAST PERIOD
4.4 ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY REGION AND TYPE
FIGURE 17 ANTIFUNGAL SUSCEPTIBILITY TESTING SEGMENT TO REGISTER SIGNIFICANT GROWTH IN THE ANTIMICROBIAL SUSCEPTIBILITY MARKET IN EUROPE
4.5 GEOGRAPHIC ANALYSIS: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY METHOD AND REGION, 2020 VS 2025, (USD MILLION)
FIGURE 18 THE AUTOMATED SUSCEPTIBILITY TESTING INSTRUMENTS SEGMENT TO WITNESS HIGH GROWTH IN THE APAC MARKET DURING THE FORECAST PERIOD
4.6 GEOGRAPHIC SNAPSHOT OF THE ANTIMICROBIAL SUSCEPTIBILITY MARKET
FIGURE 19 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 55)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 ANTIMICROBIAL SUSCEPTIBILITY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of infectious diseases coupled with epidemic & pandemic events
5.2.1.2 Increasing funding, research grants, and public-private investments in the market
5.2.1.3 Technological advancements
5.2.1.4 Growing government initiatives to detect and control antimicrobial-resistant species
5.2.1.5 Emergence of multidrug-resistance due to drug abuse
5.2.2 RESTRAINTS
5.2.2.1 High cost of automated ID/AST systems
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Awareness initiatives for antimicrobial resistance and its control
5.2.4 CHALLENGES
5.2.4.1 Complex regulatory frameworks that delay antimicrobial testing approvals
5.3 IMPACT OF THE COVID-19 ON THE ANTIMICROBIAL SUSCEPTIBILITY MARKET
5.4 ECOSYSTEM ANALYSIS
FIGURE 21 ECOSYSTEM ANALYSIS OF THE OVERALL AST MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: MAXIMUM VALUE-ADDED DURING MANUFACTURING PHASE
5.6 REGULATORY ANALYSIS
5.6.1 NORTH AMERICA
5.6.1.1 US
TABLE 2 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 3 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.6.1.2 Canada
TABLE 4 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 23 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
5.6.2 EUROPE
FIGURE 24 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR)
5.6.3 ASIA PACIFIC
5.6.3.1 Japan
TABLE 5 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
5.6.3.2 China
TABLE 6 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.6.3.3 India
6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT (Page No. - 74)
6.1 INTRODUCTION
TABLE 7 ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
6.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 8 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 9 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.2.1 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 10 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, 2018–2025 (USD MILLION)
6.2.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 11 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.2.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 12 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD, 2018–2025 (USD MILLION)
6.2.4 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 13 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER, 2018–2025 (USD MILLION)
6.2.5 SUSCEPTIBILITY TESTING DISKS
6.2.5.1 Significant adoption of disk diffusion tests in emerging countries to support segment growth
TABLE 14 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.2.5.2 Susceptibility testing disks market, by type, 2018–2025 (USD million)
TABLE 15 SUSCEPTIBILITY TESTING DISKS MARKET, BY TYPE, 2018–2025 (USD MILLION)
6.2.5.3 Susceptibility testing disks market, by application, 2018–2025 (USD million)
TABLE 16 SUSCEPTIBILITY TESTING DISKS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.2.5.4 Susceptibility testing disks market, by method, 2018–2025 (USD million)
TABLE 17 SUSCEPTIBILITY TESTING DISKS MARKET, BY METHOD, 2018–2025 (USD MILLION)
6.2.5.5 Susceptibility testing disks market, by end user, 2018–2025 (USD million)
TABLE 18 SUSCEPTIBILITY TESTING DISKS MARKET, BY END USER, 2018–2025 (USD MILLION)
6.2.6 MIC STRIPS
6.2.6.1 Growing adoption of broad-spectrum MIC strips to support market growth
TABLE 19 MIC STRIPS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.2.6.2 MIC strips market, by type, 2018–2025 (USD million)
TABLE 20 MIC STRIPS MARKET, BY TYPE, 2018–2025 (USD MILLION)
6.2.6.3 MIC strips market, by application, 2018–2025 (USD million)
TABLE 21 MIC STRIPS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.2.6.4 MIC strips market, by method, 2018–2025 (USD million)
TABLE 22 MIC STRIPS MARKET, BY METHOD, 2018–2025 (USD MILLION)
6.2.6.5 MIC STRIPS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 23 MIC STRIPS MARKET, BY END USER, 2018–2025 (USD MILLION)
6.2.7 SUSCEPTIBILITY TESTING PLATES
6.2.7.1 Growing adoption of automated/rapid AST systems is hampering the growth of this segment
TABLE 24 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION, 2018–2025 (USD MILLION)
6.2.7.2 Susceptibility testing plates market, by type, 2018–2025 (USD million)
TABLE 25 SUSCEPTIBILITY TESTING PLATES MARKET, BY TYPE, 2018–2025 (USD MILLION)
6.2.7.3 Susceptibility testing plates market, by application, 2018–2025 (USD million)
TABLE 26 SUSCEPTIBILITY TESTING PLATES MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.2.7.4 Susceptibility testing plates market, by method, 2018–2025 (USD million)
TABLE 27 SUSCEPTIBILITY TESTING PLATES MARKET, BY METHOD, 2018–2025 (USD MILLION)
6.2.7.5 Susceptibility testing plates market, by end user, 2018–2025 (USD million)
TABLE 28 SUSCEPTIBILITY TESTING PLATES MARKET, BY END USER, 2018–2025 (USD MILLION)
6.3 AUTOMATED LABORATORY INSTRUMENTS
6.3.1 THE ONGOING TREND OF LABORATORY AUTOMATION AMONG CLINICAL LABORATORIES WILL FUEL SEGMENT GROWTH
TABLE 29 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.3.2 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 30 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
6.3.3 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 31 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.3.4 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 32 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD, 2018–2025 (USD MILLION)
6.3.5 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 33 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER, 2018–2025 (USD MILLION)
6.4 CULTURE AND GROWTH MEDIA
6.4.1 HIGH UTILIZATION OF DISK DIFFUSION AND BROTH DILUTION METHODS TO DRIVE THE SEGMENT GROWTH
TABLE 34 CULTURE AND GROWTH MEDIA MARKET, BY REGION, 2018–2025 (USD MILLION)
6.4.2 CULTURE AND GROWTH MEDIA MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 35 CULTURE AND GROWTH MEDIA MARKET, BY TYPE, 2018–2025 (USD MILLION)
6.4.3 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 36 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.4.4 CULTURE AND GROWTH MEDIA MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 37 CULTURE AND GROWTH MEDIA MARKET, BY METHOD, 2018–2025 (USD MILLION)
6.4.5 CULTURE AND GROWTH MEDIA MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 38 CULTURE AND GROWTH MEDIA MARKET, BY END USER, 2018–2025 (USD MILLION)
6.5 CONSUMABLES
6.5.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED AT HOSPITALS TO SUPPORT THE CONSUMABLES SEGMENT
TABLE 39 CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
6.5.2 CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 40 CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
6.5.3 CONSUMABLES MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 41 CONSUMABLES MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
6.5.4 CONSUMABLES MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 42 CONSUMABLES MARKET, BY METHOD, 2018–2025 (USD MILLION)
6.5.5 CONSUMABLES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 43 CONSUMABLES MARKET, BY END USER, 2018–2025 (USD MILLION)
7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE (Page No. - 97)
7.1 INTRODUCTION
TABLE 44 ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING
7.2.1 THE EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 45 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018–2025 (USD MILLION)
7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING
7.3.1 INCREASING CANDIDA AND ASPERGILLUS SPECIES FUNGAL INFECTIONS ARE MAJOR FACTORS DRIVING SEGMENT GROWTH
TABLE 46 NUMBER OF HOSPITALIZATIONS AND DIRECT MEDICAL COSTS ASSOCIATED WITH FUNGAL DISEASES IN THE UNITED STATES FOR FY 2017
TABLE 47 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018–2025 (USD MILLION)
7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING
7.4.1 RISING INITIATIVES TO CREATE AWARENESS ABOUT PARASITIC INFECTIONS TO DRIVE SEGMENT GROWTH FOR PRODUCTS
TABLE 48 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018–2025 (USD MILLION)
7.5 OTHER SUSCEPTIBILITY TESTING TYPES
7.5.1 COMPLEXITY ASSOCIATED WITH FASTIDIOUS PATHOGEN TESTING TO HAMPER THE GROWTH OF THIS SEGMENT
TABLE 49 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER SUSCEPTIBILITY TESTING TYPES, BY REGION, 2018–2025 (USD MILLION)
8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION (Page No. - 103)
8.1 INTRODUCTION
TABLE 50 ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
8.2 CLINICAL DIAGNOSTICS
8.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED DRIVE SEGMENT GROWTH
TABLE 51 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2018–2025 (USD MILLION)
8.3 DRUG DISCOVERY AND DEVELOPMENT
8.3.1 RISING ADOPTION OF RAPID AST SOLUTIONS BY BIOPHARMACEUTICAL COMPANIES TO DRIVE SEGMENT GROWTH
TABLE 52 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018–2025 (USD MILLION)
8.4 EPIDEMIOLOGY
8.4.1 OUTBREAK OF PANDEMIC AND EPIDEMIC SITUATIONS TO DRIVE DEMAND FOR AST PRODUCTS
TABLE 53 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY, BY REGION, 2018–2025 (USD MILLION)
8.5 OTHER APPLICATIONS
8.5.1 GROWING ADOPTION OF AST PRODUCTS FOR BIOTERRORISM SURVEILLANCE TO FUEL SEGMENT GROWTH
TABLE 54 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD (Page No. - 109)
9.1 INTRODUCTION
TABLE 55 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2018–2025 (USD MILLION)
9.2 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING INSTRUMENTS
9.2.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE TO DRIVE SEGMENT GROWTH
TABLE 56 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING INSTRUMENTS, BY REGION, 2018–2025 (USD MILLION)
9.3 DISK DIFFUSION
9.3.1 RISING INCIDENCES OF URINARY TRACT INFECTIONS TO DRIVE SEGMENT GROWTH
TABLE 57 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISK DIFFUSION, BY REGION, 2018–2025 (USD MILLION)
9.4 AGAR DILUTION
9.4.1 AGAR DILUTION HELPS EXPLORE DRUG COMBINATIONS FOR COMBINED ANTIBIOTIC THERAPY
TABLE 58 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR AGAR DILUTION, BY REGION, 2018–2025 (USD MILLION)
9.5 ETEST METHOD
9.5.1 UNCERTAINTIES IN RESULT INTERPRETATION HAMPERS THE ADOPTION OF THIS METHOD
TABLE 59 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR ETEST METHOD, BY REGION, 2018–2025 (USD MILLION)
9.6 GENOTYPIC METHODS
9.6.1 ONGOING CLINICAL TRIALS AND UPCOMING PRODUCT LAUNCHES SUPPORT SEGMENT GROWTH
TABLE 60 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR GENOTYPIC METHODS, BY REGION, 2018–2025 (USD MILLION)
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER (Page No. - 117)
10.1 INTRODUCTION
TABLE 61 ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY END USER, 2018–2025 (USD MILLION)
10.2 HOSPITALS AND DIAGNOSTIC CENTERS
10.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES COUPLED WITH THE RISING ADOPTION OF RAPID AST SOLUTIONS TO DRIVE SEGMENT GROWTH
TABLE 62 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2018–2025 (USD MILLION)
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.3.1 INCREASING NUMBER OF BIOPHARMACEUTICAL COMPANIES TO SUPPORT SEGMENT GROWTH
FIGURE 25 ANTIMICROBIAL RESISTANCE RELATED R&D PROJECTS BY KEY PLAYERS, 2020
TABLE 63 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION)
10.4 RESEARCH & ACADEMIC INSTITUTES
10.4.1 GROWING RESEARCH GRANTS AND FUNDING IS ACCELERATING THE GROWTH OF THIS SEGMENT
TABLE 64 FUNDING BY THE DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020
TABLE 65 ANTIMICROBIAL SUSCEPTIBILITY MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018–2025 (USD MILLION)
10.5 CONTRACT RESEARCH ORGANIZATIONS
10.5.1 CLINICAL TRIAL GLOBALIZATION AND THE GROWING NUMBER OF CROS IN EMERGING ECONOMIES DRIVES MARKET GROWTH
TABLE 66 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION)
11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION (Page No. - 124)
11.1 INTRODUCTION
TABLE 67 ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY REGION, 2018–2025 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET SNAPSHOT
TABLE 68 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 69 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT 2018–2025 (USD MILLION)
TABLE 70 NORTH AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 71 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 72 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 73 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 74 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY END USER, 2018–2025 (USD MILLION)
11.2.1 US
11.2.1.1 The US dominated the North American AST market in 2019
TABLE 75 US: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 76 US: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Favorable government initiatives to market growth during the forecast period
TABLE 77 CANADA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 78 CANADA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.3 EUROPE
TABLE 79 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 80 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT 2018–2025 (USD MILLION)
TABLE 81 EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 83 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 84 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 85 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY END USER, 2018–2025 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany dominated the European antimicrobial susceptibility testing market in 2019
TABLE 86 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 87 GERMANY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Supportive government policies and easy accessibility to healthcare services to fuel market growth in France
TABLE 88 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 89 FRANCE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.3.3 UK
11.3.3.1 The significant prevalence of infectious diseases coupled with increasing awareness for AST products to drive market growth
TABLE 90 UK: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT. 2018–2025 (USD MILLION)
TABLE 91 UK: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Increasing R&D investments by pharmaceutical companies will propel the demand for AST products in Italy
TABLE 92 ITALY: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 93 ITALY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Rising geriatric population in Spain to drive market growth for AST procedures
TABLE 94 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 95 SPAIN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.3.6 REST OF EUROPE (ROE)
TABLE 96 ROE: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 97 ROE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY MARKET SNAPSHOT
TABLE 98 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 99 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 100 ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 101 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 102 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 103 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 104 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY END USER, 2018–2025 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Rising initiatives for the development of innovative screening technologies and growing geriatric population to drive market growth in Japan
TABLE 105 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 106 JAPAN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Favorable government regulations and the heavy burden of infectious diseases to drive market growth in China
FIGURE 28 INCIDENTS OF INFECTIOUS DISEASES IN CHINA, 2019
TABLE 107 CHINA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 108 CHINA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growing initiatives for clinical diagnosis by the government and major players in the market to drive market growth
TABLE 109 INDIA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 110 INDIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Increasing government funding for research activities to deliver novel products drives the market growth
TABLE 111 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 112 AUSTRALIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 The requirement of rapid AMR detection to drive the automated AST systems segment in South Korea
TABLE 113 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 114 SOUTH KOREA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 115 ROAPAC: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 116 ROAPAC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.5 LATIN AMERICA
TABLE 117 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 118 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 119 LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 120 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 121 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 122 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 123 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY END USER, 2018–2025 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 The established presence of major AST product manufacturers drives the market growth in Brazil
TABLE 124 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 125 BRAZIL: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 The growing economic development of the country draws increasing investments, thus driving market growth
TABLE 126 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 127 MEXICO: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 128 ROLATAM: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 129 ROLATAM: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH
TABLE 130 MEA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 131 MEA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, 2018–2025 (USD MILLION)
TABLE 132 MEA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 133 MEA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 134 MEA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY METHOD, 2018–2025 (USD MILLION)
TABLE 135 MEA: ANTIMICROBIAL SUSCEPTIBILITY MARKET, BY END USER, 2018–2025 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 170)
12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS
FIGURE 29 GLOBAL ANTIMICROBIAL SUSCEPTIBILITY MARKET SHARE, BY KEY PLAYER, 2019
12.3 COMPETITIVE SCENARIO
12.3.1 PRODUCT LAUNCHES AND APPROVALS
12.3.2 ACQUISITIONS
12.3.3 AGREEMENTS AND COLLABORATIONS
12.3.4 EXPANSIONS
13 COMPANY EVOLUTION MATRIX AND COMPANY PROFILES (Page No. - 174)
13.1 COMPETITIVE EVOLUTION MATRIX AND METHODOLOGY
13.1.1 COMPETITIVE LEADERSHIP MAPPING: MAJOR MARKET PLAYERS (2019)
13.1.1.1 Visionary leaders
13.1.1.2 Innovators
13.1.1.3 Dynamic differentiators
13.1.1.4 Emerging companies
FIGURE 30 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019 (OVERALL MARKET)
13.1.2 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (2019)
13.1.2.1 Progressive companies
13.1.2.2 Starting blocks
13.1.2.3 Responsive companies
13.1.2.4 Dynamic companies
FIGURE 31 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019 (SME/START-UPS)
13.2 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.2.1 BIOMÉRIEUX SA
FIGURE 32 BIOMÉRIEUX SA: COMPANY SNAPSHOT
13.2.2 BECTON, DICKINSON AND COMPANY
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
13.2.3 THERMO FISHER SCIENTIFIC
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
13.2.4 DANAHER CORPORATION
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT
13.2.5 BIO-RAD LABORATORIES, INC.
FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
13.2.6 BRUKER
FIGURE 37 BRUKER: COMPANY SNAPSHOT
13.2.7 ROCHE DIAGNOSTICS
FIGURE 38 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
13.2.8 MERCK KGAA
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT
13.2.9 ACCELERATE DIAGNOSTICS, INC.
FIGURE 40 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT
13.2.10 HIMEDIA LABORATORIES
13.2.11 LIOFILCHEM S.R.L.
13.2.12 ALIFAX S.R.L.
13.2.13 CREATIVE DIAGNOSTICS
13.2.14 SYNBIOSIS
13.2.15 BIOANALYSE
13.2.16 OTHER COMPANIES
13.2.16.1 ZHUHAI DL BIOTECH Co., Ltd.
13.2.16.2 ELITechGroup
13.2.16.3 Mast Group Ltd.
13.2.16.4 CONDALAB
13.2.16.5 Genefluidics, Inc.
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 212)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the antimicrobial susceptibility testing (AST) market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Primary research was conducted after acquiring extensive knowledge about the global AST market scenario through secondary research. Primary interviews were conducted with market experts from both the demand-side (such as CROs, hospitals, transplant centers, healthcare service providers, commercial service providers, academia, and research organizations) and supply-side respondents (such as presidents, CEOs, vice presidents, directors, general managers, heads of business units, and senior managers) across five major geographies, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa. Approximately 60% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 40%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Estimation Methodology
A detailed market estimation approach was followed to estimate and validate the size of the global AST market and other dependent submarkets.
- The key players in the global AST market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights on the global AST market.
- All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.
- All the possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation:
After deriving the overall AST market value data from the market size estimation process, the total market value data was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all the segments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various qualitative and quantitative variables as well as by analyzing regional trends for both the demand- and supply-side macroindicators.
Report Objectives:
- To define, describe, and forecast the AST market on the basis of product, type, method, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global AST market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the global AST market
- To analyze key growth opportunities in the global AST market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa
- To profile the key players in the global AST market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global AST market, such as product launches; agreements, partnerships, and collaborations; expansions; and mergers & acquisitions
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global antimicrobial susceptibility testing market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Rest of Europe antimicrobial susceptibility testing market into Belgium, Austria, the Czech Republic, Denmark, Greece, Poland, and Russia, among other
- Further breakdown of the Rest of Asia Pacific antimicrobial susceptibility testing market into wan, New Zealand, Vietnam, the Philippines, Singapore, Malaysia, Thailand, and Indonesia among other
- Further breakdown of the Latin American antimicrobial susceptibility testing market into Argentina, Chile, Peru, and Colombia, among other
Growth opportunities and latent adjacency in Antimicrobial Susceptibility Testing Market